FIRST AMENDMENT TO SEVERANCE and CHANGE IN CONTROL AGREEMENTSeverance and Change in Control Agreement • March 5th, 2020 • Zafgen, Inc. • Pharmaceutical preparations • Massachusetts
This First Amendment to Severance and Change in Control Agreement (this “Amendment”) is entered into and effective as of September 12, 2019, by and between Zafgen, Inc., a Delaware corporation (the “Company”), and Priya Singhal, MD (the “Employee”).
BOSTON, MASSACHUSETTS 02108Zafgen, Inc. • March 5th, 2020 • Pharmaceutical preparations • Delaware
As you know, Zafgen, Inc. (the “Company”) has entered into an Agreement and Plan of Merger, by and among Chondrial Therapeutics, Inc., (“Chondrial”), Chondrial Therapeutics Holdings, LLC, and Zordich Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), pursuant to which Chondrial will be merged with and into Merger Sub (the “Merger”), with Chondrial continuing after the Merger as the surviving company and a wholly-owned subsidiary of the Company. In connection with the Merger, the Board of Directors of the Company (the “Board”) is pleased to offer you the following amendment to the terms of your option to purchase 1,100,000 shares of the Company’s common stock, granted on October 9, 2017 (the “Performance Option”):
